KROS: Keros Therapeutics Inc

KROS新闻

• 17:30 Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
• 13:17 KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
• 12:04 Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
• 12:04 Keros Therapeutics预计在ELRiSE MF临床试验首位患者给药后，依据其与武田的Elritercept许可协议将获得2000万美元的开发里程碑付款
• 12:03 Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy
• 15:30 Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
• 16:53 KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
• 16:51 Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
• 14:43 KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
• 09:05 New Strong Sell Stocks for July 30th
• 12:15 Incyte (INCY) Q2 Earnings and Revenues Top Estimates
• 14:41 Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
• 23:18 Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• 15:10 KROS Turns to Next Wave of TGF-Beta Muscle Therapies
• 15:10 KROS Turns to Next Wave of TGF-Beta Muscle Therapies
• 15:06 Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
• 15:06 Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
• 15:03 KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
• 15:03 KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
• 16:08 Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
• 13:10 Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
• 21:35 Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
• 21:10 Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
• 15:41 KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment